Latest Conference Articles

January 16th 2021, 6:56pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

January 16th 2021, 6:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.

January 16th 2021, 4:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

January 16th 2021, 3:15pm

ASCO GI 2021 News

3

January 16th 2021, 3:15pm

ASCO GI 2021 News

2

January 16th 2021, 3:15pm

ASCO GI 2021 News

1

January 16th 2021, 3:30am

Gastrointestinal Cancers Symposium (ASCO GI)

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

January 15th 2021, 10:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

January 15th 2021, 9:45pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.

January 15th 2021, 9:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.

January 15th 2021, 9:22pm

Gastrointestinal Cancers Symposium (ASCO GI)

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.

January 15th 2021, 9:18pm

Gastrointestinal Cancers Symposium (ASCO GI)

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

January 15th 2021, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Combination treatment with adjuvant S-1 and docetaxel led to an estimated 29% reduction in the risk of relapse compared with S-1 alone in patients with stage III gastric cancer.

January 15th 2021, 8:08pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.

January 15th 2021, 8:01pm

January 15, 2021 - One-year overall survival was found increased the longer that patients with metastatic pancreatic ductal adenocarcinoma remained on treatment with liposomal irinotecan plus 5-fluorouracil/leucovorin.

January 15th 2021, 7:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Pembrolizumab with trastuzumab and the combination of cisplatin and capecitabine appeared effective in treating HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of a patient’s PD-L1 status.

January 15th 2021, 7:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.

January 15th 2021, 6:12pm

January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.

January 15th 2021, 5:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.

January 15th 2021, 5:01pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them